CN114245744A - 器官损伤的预防和治疗 - Google Patents
器官损伤的预防和治疗 Download PDFInfo
- Publication number
- CN114245744A CN114245744A CN202180001578.7A CN202180001578A CN114245744A CN 114245744 A CN114245744 A CN 114245744A CN 202180001578 A CN202180001578 A CN 202180001578A CN 114245744 A CN114245744 A CN 114245744A
- Authority
- CN
- China
- Prior art keywords
- infection
- compound
- lung
- respiratory
- injury
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pulmonology (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Materials For Medical Uses (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110951301.2A CN113694177B (zh) | 2020-04-15 | 2021-04-15 | 器官损伤的预防和治疗 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNPCT/CN2020/084820 | 2020-04-15 | ||
| CN2020084820 | 2020-04-15 | ||
| CNPCT/CN2021/081574 | 2021-03-18 | ||
| CN2021081574 | 2021-03-18 | ||
| PCT/CN2021/087501 WO2021209003A1 (en) | 2020-04-15 | 2021-04-15 | Prevention and treatment of organ injuries |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110951301.2A Division CN113694177B (zh) | 2020-04-15 | 2021-04-15 | 器官损伤的预防和治疗 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN114245744A true CN114245744A (zh) | 2022-03-25 |
Family
ID=78085285
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202180001578.7A Pending CN114245744A (zh) | 2020-04-15 | 2021-04-15 | 器官损伤的预防和治疗 |
| CN202110951301.2A Active CN113694177B (zh) | 2020-04-15 | 2021-04-15 | 器官损伤的预防和治疗 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110951301.2A Active CN113694177B (zh) | 2020-04-15 | 2021-04-15 | 器官损伤的预防和治疗 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US12465629B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4135743A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2023521161A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20230002589A (cg-RX-API-DMAC7.html) |
| CN (2) | CN114245744A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021256222A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3174545A1 (cg-RX-API-DMAC7.html) |
| TW (1) | TWI889805B (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021209003A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3172535A1 (en) | 2020-03-26 | 2021-09-30 | Ching-Pong Mak | Cyclophilin inhibitors and uses thereof |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0194972B1 (en) | 1985-03-11 | 1992-07-29 | Sandoz Ag | Novel cyclosporins |
| FI111730B (fi) | 1990-11-02 | 2003-09-15 | Novartis Ag | Menetelmä ei-immunosuppressiivisen syklosporiinin valmistamiseksi |
| JPH08298986A (ja) * | 1995-04-28 | 1996-11-19 | Asahi Chem Ind Co Ltd | ホスホリパーゼa2酵素 |
| KR970064620A (ko) | 1996-03-05 | 1997-10-13 | 임성기 | 사이클로스포린-함유 외용약제 조성물 |
| ATE254630T1 (de) | 1998-06-12 | 2003-12-15 | Chem Ag C | Cyclosporine |
| CN101068829B (zh) | 2004-10-01 | 2012-05-30 | 西尼克斯公司 | 用于治疗和预防丙型肝炎病毒感染的3-醚和3-硫醚取代的环孢菌素衍生物 |
| PT1802650E (pt) * | 2004-10-01 | 2011-12-30 | Scynexis Inc | Derivados da ciclosporina 3-éter e 3-tioéter substituída para o tratamento e prevenção da infecção de hepatite c |
| WO2007041632A2 (en) * | 2005-09-30 | 2007-04-12 | Scynexis, Inc. | Methods and pharmaceutical compositions for the treatment and prevention of hepatitis c infection |
| BRPI0708424A2 (pt) | 2006-03-02 | 2011-05-31 | Alexion Pharma Inc | prolongamento da sobreviência de uma aloenxerto por inibição da atividade do complemento |
| CA2652662C (en) * | 2006-05-19 | 2015-11-03 | Scynexis, Inc. | Methods for the treatment and prevention of ocular disorders |
| WO2008143996A1 (en) | 2007-05-18 | 2008-11-27 | Scynexis, Inc. | New chemical processes |
| US8536114B2 (en) | 2008-12-31 | 2013-09-17 | Scynexis, Inc. | Macrocycles |
| US9217015B2 (en) | 2010-07-16 | 2015-12-22 | S&T Global Inc. | Cyclosporin derivatives for the treatment and prevention of a viral infection |
| MX350746B (es) * | 2010-12-03 | 2017-09-14 | Hebei Kunxiangjishi Pharmaceutical Tech Co Ltd | Derivados de ciclosporina novedosos para el tratamiento y la prevención de una infección viral. |
| GB201217560D0 (en) | 2012-10-02 | 2012-11-14 | Mitopharm Ltd | Novel cyclic depsipeptide compounds and their uses |
| TW201639873A (zh) | 2015-01-08 | 2016-11-16 | 歐樂根公司 | Mebmt側鏈已環化之環孢菌素衍生物 |
| CN105983095B (zh) * | 2015-02-15 | 2019-09-13 | 艾棣维欣(苏州)生物制药有限公司 | 一种呼吸道合胞体病毒疫苗及其制备方法与应用 |
| CN106902346A (zh) | 2015-12-23 | 2017-06-30 | 中美华世通生物医药科技(武汉)有限公司 | 药物组合物及其制药用途 |
| CN106902347A (zh) * | 2015-12-23 | 2017-06-30 | 中美华世通生物医药科技(武汉)有限公司 | 亲环孢素抑制剂的用途 |
| GB201711749D0 (en) * | 2017-07-21 | 2017-09-06 | Cypralis Ltd | Cyclosporin analogues and uses thereof |
| CN111449050A (zh) | 2019-01-20 | 2020-07-28 | 睿诺医疗科技(上海)有限公司 | 环孢菌素类似物及其用途 |
| CN116870135A (zh) * | 2019-10-12 | 2023-10-13 | 睿诺医疗科技(上海)有限公司 | 肾毒素诱发的肾损伤的治疗和预防 |
| CA3172535A1 (en) | 2020-03-26 | 2021-09-30 | Ching-Pong Mak | Cyclophilin inhibitors and uses thereof |
| WO2021190603A1 (en) | 2020-03-26 | 2021-09-30 | Farsight Medical Technology (Shanghai) Co., Ltd. | Cyclophilin inhibitors and uses thereof |
-
2021
- 2021-04-15 AU AU2021256222A patent/AU2021256222A1/en not_active Abandoned
- 2021-04-15 CN CN202180001578.7A patent/CN114245744A/zh active Pending
- 2021-04-15 US US17/995,992 patent/US12465629B2/en active Active
- 2021-04-15 KR KR1020227038978A patent/KR20230002589A/ko active Pending
- 2021-04-15 WO PCT/CN2021/087501 patent/WO2021209003A1/en not_active Ceased
- 2021-04-15 TW TW110113545A patent/TWI889805B/zh active
- 2021-04-15 CN CN202110951301.2A patent/CN113694177B/zh active Active
- 2021-04-15 EP EP21788345.3A patent/EP4135743A4/en active Pending
- 2021-04-15 CA CA3174545A patent/CA3174545A1/en active Pending
- 2021-04-15 JP JP2022561995A patent/JP2023521161A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| TW202143995A (zh) | 2021-12-01 |
| CA3174545A1 (en) | 2021-10-21 |
| CN113694177B (zh) | 2022-06-17 |
| AU2021256222A1 (en) | 2022-10-06 |
| EP4135743A4 (en) | 2024-05-22 |
| CN113694177A (zh) | 2021-11-26 |
| US20230181680A1 (en) | 2023-06-15 |
| WO2021209003A1 (en) | 2021-10-21 |
| KR20230002589A (ko) | 2023-01-05 |
| EP4135743A1 (en) | 2023-02-22 |
| TWI889805B (zh) | 2025-07-11 |
| US12465629B2 (en) | 2025-11-11 |
| JP2023521161A (ja) | 2023-05-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11219611B2 (en) | Formulations of L-ornithine phenylacetate | |
| JP6837835B2 (ja) | トレハロースの非経口投与によるタンパク質凝集ミオパシーおよび神経変性疾患の治療 | |
| JP2003510275A (ja) | ロテプレドノールと抗ヒスタミン薬の新規な組み合わせ物 | |
| CN107835695A (zh) | 用于治疗自闭症的组合物和方法 | |
| CN113694177B (zh) | 器官损伤的预防和治疗 | |
| EP2608783A1 (en) | Use of glycyrrhetinic acid, glycyrrhizic acid and related compounds for prevention and/or treatment of pulmonary fibrosis | |
| RU2012116226A (ru) | Бронхолитическое средство на основе простагландина | |
| CN118806741A (zh) | 二氢青蒿酸在制备预防或治疗急性肺损伤的药物中的应用 | |
| JP2018127489A (ja) | 禁煙のためのβ−アドレナリン作動性インバースアゴニストの使用 | |
| WO2023100127A1 (en) | Pharmaceutical composition comprising ibuprofen and arginine | |
| US20170216298A1 (en) | Beta2-ADRENOCEPTOR AGONIST FOR THE TREATMENT OF COUGH | |
| US20110117213A1 (en) | Treatment of acute exacerbation of asthma and reduction of likelihood of hospitalization of patients suffering therefrom | |
| TW202504602A (zh) | 用於治療臟器纖維化相關疾病的藥物組合物和方法 | |
| CN105273031B (zh) | 新颖的三萜化合物及其用途 | |
| CN106692976B (zh) | P-糖蛋白抑制剂Gelucire44/14作为经口服的盐酸小檗碱吸收促进剂的应用 | |
| RU2451507C2 (ru) | Лекарственное средство для лечения хронического обструктивного заболевания легких | |
| RU2043765C1 (ru) | Способ лечения хронических неспецифических заболеваний легких | |
| AU2017251548A1 (en) | Inhaled preparation of isoglycyrrhizic acid or salt thereof and use in preparing drugs for treating respiratory system diseases | |
| JP2016027032A (ja) | 慢性閉塞性肺疾患治療剤 | |
| EP4709379A1 (en) | Nmdar antagonist for the treatment of inflammatory diseases in patients with depression comorbidity | |
| TWI527828B (zh) | 新穎的三萜化合物及其用途 | |
| US20210267955A1 (en) | Low dose oral pharmaceutical composition of pirfenidone or salt thereof | |
| Mahendran | A Comparative study on three doses of Esmolol to attenuate the Hemo Dynamic Stress Response during Laryngoscopy and Endo Tracheal Intubation | |
| KR20130038583A (ko) | 소포체 스트레스 억제제를 유효성분으로 함유하는 급성 폐 손상의 예방 또는 치료용 약학 조성물 | |
| WO2012115946A1 (en) | Treating human male copd patients with oral bedoradrine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |